Efficient recovery of endothelial progenitors for clinical translation

Bryan W. Tillman, Saami K. Yazdani, Randolph L. Geary, Matthew A. Corriere, Anthony Atala, James J. Yoo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Circulating autologous CD133+ stem cells have been differentiated into a number of cell types that have the potential for clinical use, including endothelial cells. These cells are infrequently found in peripheral blood specimens, and this limits their use in clinical applications. To address this problem, we have developed an extracorporeal cellular affinity (ECA) column that can recover CD133 expressing progenitor cells with high efficiency. Methods and Results: In sheep model, 1800 xmL of blood was passed through a Sepharose-based column with affinity for CD133. Unbound cells and plasma were returned to the animal. Our results show that this process has a minimal effect on the hematologic and physiologic parameters of the animal. This recovery approach generated over 600-fold more endothelial colony forming units than conventional buffy leukocytes isolated from a peripheral blood specimen. Ultimately, the increased cell recovery of the ECA column enables the generation of a cell biomass for therapeutic purposes in nearly a third of the time. Conclusions: This technology may facilitate the generation of large numbers of progenitor-derived cells for clinical therapies and reduce the time required to attain clinically relevant cell numbers while minimizing loss of other important cell types to the donor.

Original languageEnglish
Pages (from-to)213-221
Number of pages9
JournalTissue Engineering - Part C: Methods
Volume15
Issue number2
DOIs
StatePublished - Jun 1 2009
Externally publishedYes

Fingerprint

Blood
Stem Cells
Recovery
Animals
Cell Count
Endothelial cells
Stem cells
Sepharose
Biomass
Cell- and Tissue-Based Therapy
Plasma Cells
Plasmas
Sheep
Leukocytes
Endothelial Cells
Technology
Therapeutics

ASJC Scopus subject areas

  • Biomedical Engineering
  • Bioengineering
  • Medicine (miscellaneous)

Cite this

Tillman, B. W., Yazdani, S. K., Geary, R. L., Corriere, M. A., Atala, A., & Yoo, J. J. (2009). Efficient recovery of endothelial progenitors for clinical translation. Tissue Engineering - Part C: Methods, 15(2), 213-221. https://doi.org/10.1089/ten.tec.2008.0416

Efficient recovery of endothelial progenitors for clinical translation. / Tillman, Bryan W.; Yazdani, Saami K.; Geary, Randolph L.; Corriere, Matthew A.; Atala, Anthony; Yoo, James J.

In: Tissue Engineering - Part C: Methods, Vol. 15, No. 2, 01.06.2009, p. 213-221.

Research output: Contribution to journalArticle

Tillman, BW, Yazdani, SK, Geary, RL, Corriere, MA, Atala, A & Yoo, JJ 2009, 'Efficient recovery of endothelial progenitors for clinical translation', Tissue Engineering - Part C: Methods, vol. 15, no. 2, pp. 213-221. https://doi.org/10.1089/ten.tec.2008.0416
Tillman, Bryan W. ; Yazdani, Saami K. ; Geary, Randolph L. ; Corriere, Matthew A. ; Atala, Anthony ; Yoo, James J. / Efficient recovery of endothelial progenitors for clinical translation. In: Tissue Engineering - Part C: Methods. 2009 ; Vol. 15, No. 2. pp. 213-221.
@article{4620e949b2c74f2c89a3495103b4db99,
title = "Efficient recovery of endothelial progenitors for clinical translation",
abstract = "Background: Circulating autologous CD133+ stem cells have been differentiated into a number of cell types that have the potential for clinical use, including endothelial cells. These cells are infrequently found in peripheral blood specimens, and this limits their use in clinical applications. To address this problem, we have developed an extracorporeal cellular affinity (ECA) column that can recover CD133 expressing progenitor cells with high efficiency. Methods and Results: In sheep model, 1800 xmL of blood was passed through a Sepharose-based column with affinity for CD133. Unbound cells and plasma were returned to the animal. Our results show that this process has a minimal effect on the hematologic and physiologic parameters of the animal. This recovery approach generated over 600-fold more endothelial colony forming units than conventional buffy leukocytes isolated from a peripheral blood specimen. Ultimately, the increased cell recovery of the ECA column enables the generation of a cell biomass for therapeutic purposes in nearly a third of the time. Conclusions: This technology may facilitate the generation of large numbers of progenitor-derived cells for clinical therapies and reduce the time required to attain clinically relevant cell numbers while minimizing loss of other important cell types to the donor.",
author = "Tillman, {Bryan W.} and Yazdani, {Saami K.} and Geary, {Randolph L.} and Corriere, {Matthew A.} and Anthony Atala and Yoo, {James J.}",
year = "2009",
month = "6",
day = "1",
doi = "10.1089/ten.tec.2008.0416",
language = "English",
volume = "15",
pages = "213--221",
journal = "Tissue Engineering - Part C: Methods",
issn = "1937-3384",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Efficient recovery of endothelial progenitors for clinical translation

AU - Tillman, Bryan W.

AU - Yazdani, Saami K.

AU - Geary, Randolph L.

AU - Corriere, Matthew A.

AU - Atala, Anthony

AU - Yoo, James J.

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Background: Circulating autologous CD133+ stem cells have been differentiated into a number of cell types that have the potential for clinical use, including endothelial cells. These cells are infrequently found in peripheral blood specimens, and this limits their use in clinical applications. To address this problem, we have developed an extracorporeal cellular affinity (ECA) column that can recover CD133 expressing progenitor cells with high efficiency. Methods and Results: In sheep model, 1800 xmL of blood was passed through a Sepharose-based column with affinity for CD133. Unbound cells and plasma were returned to the animal. Our results show that this process has a minimal effect on the hematologic and physiologic parameters of the animal. This recovery approach generated over 600-fold more endothelial colony forming units than conventional buffy leukocytes isolated from a peripheral blood specimen. Ultimately, the increased cell recovery of the ECA column enables the generation of a cell biomass for therapeutic purposes in nearly a third of the time. Conclusions: This technology may facilitate the generation of large numbers of progenitor-derived cells for clinical therapies and reduce the time required to attain clinically relevant cell numbers while minimizing loss of other important cell types to the donor.

AB - Background: Circulating autologous CD133+ stem cells have been differentiated into a number of cell types that have the potential for clinical use, including endothelial cells. These cells are infrequently found in peripheral blood specimens, and this limits their use in clinical applications. To address this problem, we have developed an extracorporeal cellular affinity (ECA) column that can recover CD133 expressing progenitor cells with high efficiency. Methods and Results: In sheep model, 1800 xmL of blood was passed through a Sepharose-based column with affinity for CD133. Unbound cells and plasma were returned to the animal. Our results show that this process has a minimal effect on the hematologic and physiologic parameters of the animal. This recovery approach generated over 600-fold more endothelial colony forming units than conventional buffy leukocytes isolated from a peripheral blood specimen. Ultimately, the increased cell recovery of the ECA column enables the generation of a cell biomass for therapeutic purposes in nearly a third of the time. Conclusions: This technology may facilitate the generation of large numbers of progenitor-derived cells for clinical therapies and reduce the time required to attain clinically relevant cell numbers while minimizing loss of other important cell types to the donor.

UR - http://www.scopus.com/inward/record.url?scp=67649861066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649861066&partnerID=8YFLogxK

U2 - 10.1089/ten.tec.2008.0416

DO - 10.1089/ten.tec.2008.0416

M3 - Article

C2 - 19125587

AN - SCOPUS:67649861066

VL - 15

SP - 213

EP - 221

JO - Tissue Engineering - Part C: Methods

JF - Tissue Engineering - Part C: Methods

SN - 1937-3384

IS - 2

ER -